Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

1. Sanofi, during a period of organizational overhaul, is restructuring its US commercial vaccine group.
2. The company aims to implement a streamlined strategic sales structure to optimize commercial structure for greater efficiency and effectiveness.
3. Sanofi is providing financial support, outplacement assistance, and opportunities for impacted employees to apply for new positions.
4. The restructuring occurs alongside an ongoing R&D overhaul, which includes layoffs and a simplified R&D structure.
5. Sanofi has been working on CEO Paul Hudson's "play to win" strategy since 2019, with a recent strategy refresh in October.
6. The company announced a plan to spin off its consumer healthcare division and a new cost-cutting initiative aiming to save up to 2 billion euros from 2024 to the end of 2025.